Human Embryonic Stem Cells market to see major growth by 2026 | Lonza Group Ltd., Life Technologies Corporation, NuVasive Inc., TiGenix NV, Sumanas,…

Global Human Embryonic Stem Cells Market Report is a professional and depth study on the present state also focuses on the major drivers, business strategists and effective growth for the key players. It provides accurate market figures and forecasts that have been calculated with the use of advanced primary and secondary research techniques. It includes deep segment analysis of the Human Embryonic Stem Cells market where the main focus is on segments by product and application. It also offers a detailed analysis of the regional growth of the Human Embryonic Stem Cells market , taking into consideration important market opportunities available across the world. Even the vendor landscape is highly focused upon with comprehensive profiling of leading companies operating in the Human Embryonic Stem Cells market.

The COVID-19 outbreak is now traveling around the world, leaving a trail of destruction in its wake. This report discusses the impact of the virus on leading companies in the Human Embryonic Stem Cells market sector.

Access PDF Version of this Report at: https://www.amplemarketreports.com/sample-request/covid-19-outbreak-global-human-embryonic-stem-cells-industry-1881855.html

The following Companies as the Key Players in the Human Embryonic Stem Cells Market Research Report are: Lonza Group Ltd., Life Technologies Corporation, NuVasive Inc., TiGenix N.V, Sumanas, Aastrom Biosciences, Cynata Therapeutics Ltd., Genlantis, Anterogen Co., Ltd, CellTherapies P/L, BioRestorative Therapies Inc., Vericel Corporation, BrainStorm Cell Therapeutics Inc., Cesca Therapeutics Inc., Kite Pharma Inc., PromoCell, Orthofix International N.V., Ocata Therapeutics Inc., Beike Biotechnology

The report includes a detailed segmentation study of the Human Embryonic Stem Cells market, where all of the segments are analyzed in terms of market growth, share, growth rate, and other vital factors. It also provides the attractiveness index of segments so that players can be informed about lucrative revenue pockets of the Human Embryonic Stem Cells market. The extensive evaluation of segments provided in the report will help you to direct your investments, strategies, and teams to focus on the right areas of the Human Embryonic Stem Cells market.

In this research study, the Human Embryonic Stem Cells market is segmented according to product type and application.

Major Types are follows: Adult Sources, Fetal Sources, Others.

Major Application are follows: Hematopoietic stem cell transplantation, Tissue repair damage, Autoimmune diseases, As gene therapy vectors..

The report also brings to light the growth prospects of leading regional markets and factors supporting their advancement.

Major Regions are: North America (Covered in Chapter 7 and 14), United States, Canada, Mexico, Europe (Covered in Chapter 8 and 14), Germany, UK, France, Italy, Spain, Russia.

Click to view Tables, Charts, Figures, TOC, and Companies Mentioned in the Human Embryonic Stem Cells Market Report at-https://www.amplemarketreports.com/report/covid-19-outbreak-global-human-embryonic-stem-cells-industry-1881855.html

Take a look at some of the important sections of the report:

Market Overview: Readers are informed about the scope of the Human Embryonic Stem Cells market and different products offered therein. The section also gives a glimpse of all of the segments studied in the report with their consumption and production growth rate comparisons. In addition, it provides statistics related to market size, revenue, and production.

Production Market Share by Region: Apart from the production share of regional markets analyzed in the report, readers are informed about their gross margin, price, revenue, and production growth rate here.

Company Profiles and Key Figures: In this section, the authors of the report include the company profiling of leading players operating in the Human Embryonic Stem Cells market. There are various factors considered for assessing the players studied in the report: markets served, production sites, price, gross margin, revenue, production, product application, product specification, and product introduction.

Manufacturing Cost Analysis: Here, readers are provided with detailed manufacturing process analysis, industrial chain analysis, manufacturing cost structure analysis, and raw materials analysis. Under raw materials analysis, the report includes details about key suppliers of raw materials, price trend of raw materials, and important raw materials.

Market Dynamics: The analysts explore critical influence factors, market drivers, challenges, risk factors, opportunities, and market trends in this section.

Get Full Report Now at https://www.amplemarketreports.com/buy-report.html?report=1881855&format=1

We follow industry best practices and primary and secondary research methodologies to prepare our market research publications. Our analysts take references from company websites, government documents, press releases, and financial reports and conduct face-to-face or telephonic interviews with industry experts for collecting information and data. There is one complete section of the report dedicated to the authors list, data sources, methodology/research approach, and publishers disclaimer. Then there is another section that includes research findings and conclusion.

We can customize the report as per your requirements. Our analysts are experts in Human Embryonic Stem Cells market research and analysis and have a healthy experience in report customization after having served tons of clients to date. The main objective of preparing the research study is to inform you about future market challenges and opportunities. The report is one of the best resources you could use to secure a strong position in the Human Embryonic Stem Cells market.

About Ample Market Research

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Attention to detail, consistency, and quality are elements we focus on. However, our mainstay remains to be knowledge, expertise, and resources to make us industry players.

Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Us

Ample Market Research & Consulting Private Limited

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: [emailprotected]

Website: http://www.amplemarketreports.com

Johnathan is Sr.Content Writer in Levee Report , He Expertise in Business Research

Excerpt from:
Human Embryonic Stem Cells market to see major growth by 2026 | Lonza Group Ltd., Life Technologies Corporation, NuVasive Inc., TiGenix NV, Sumanas,...

Stem Cell Banking Market Industry Analysis & Forecast (2019-2026) by Type, Service, Application and Geography. – Good Night, Good Hockey

Stem Cell Banking Market was valued US$ XX Mn in 2018 and is expected to reach US$ XX Mn by 2026, at a XX% CAGR of around during a forecast period.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/13540

A stem cell bank is a facility, which stores stem cells for future use. Stem cell banking is the process of conserving stem cells at temperatures below the freezing point. These cells used for the treatment of Parkinsons syndrome, cancer, diabetes, heart diseases, and others.

The major driving factors of the market growth are an increase in research and development activities in regards to applications of stem cells and a rise in the prevalence of fatal chronic diseases. The large number of births occurring worldwide and growth in GDP & disposable income are expected to further boost the market growth. Additionally, an initiative taken by organizations and companies to spread awareness in regards to the benefits of stem cells and untapped market in the developing regions are expected to fuel the market growth. However, high processing & storage costs and lack of acceptance and awareness in developing economies adversely affect market growth.

The report covers the segments in the pontoon boat market such as tube, service, and application. Based on service type, the sample preservation & storage segment is expected to hold maximum market share during the forecast period due to the increasing adoption of stem cell banking services in key countries, growing numbers of stem cell banks across developing countries, increasing public consciousness about the therapeutic applications of stem cells.

By application, the personalized banking applications segment is the fastest-growing segment owing to increasing adoption of precision medicine across established countries, the growing prevalence of blood & immune system-related disorders among new-borns & children, &growing public worries regarding the clinical abuse of stored stem cell samples.

North America is expected to hold the largest market share during the forecast period. The increasing network of stem cell banking services, ongoing support of stem cell lines for various disease treatment, new technological developments in the field of stem cell collection & preservation techniques, increasing public-private investments for stem cell researches, rising number of stem cell transplantation procedures are pouring the growth of the Stem Cell Banking Market in North America.

LifeCodexx AG, a Provider of non-invasive prenatal DNA testing in Europe, declared its partnership with LifeCell International Pvt. Ltd., an Indian mother & baby preventive health care Type, to bring PrenaTesT, qNIPT testing for the first time to India. The qNIPT technology, which detects the presence of foetal trisomy 21 (Down Syndrome) from maternal blood, received CE marking (European Conformity) in December 2016.

Cordlife Group Limited and China Cord Blood Corporation announced that the two companies collaborated in order to support patients across the China, Singapore, Hong Kong, Indonesia, India, the Philippines, and Malaysia to identify suitable cord blood matching units for stem cell therapy.

The objective of the report is to present a comprehensive analysis of the Global Stem Cell Banking Materials Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Stem Cell Banking Materials Market dynamics, structure by analyzing the market segments and project the Global Stem Cell Banking Materials Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Stem Cell Banking Materials Market make the report investors guide. Scope of the report Stem Cell Banking Market:

Stem Cell Banking Market, by Type:

Umbilical Cord Stem Cell Adult Stem Cell Embryonic Stem Cell Stem Cell Banking Market, by Service Type

Storage Analysis Processing Collection & Transportation Stem Cell Banking Market, by Application

Cerebral Palsy Thalassemia Cancer Diseases Diabetes Autism Stem Cell Banking Market, by region

North America Europe APAC Latin America MEA Key Players Stem Cell Banking Market:

1. CCBC 2. CBR Systems, Inc. 3. ViaCord 4. Esperite 5. Vcanbio 6. Boyalife 7. LifeCell 8. Crioestaminal 9. RMS Regrow 10. Cryo-cell 11. Cordlife Group 12. PBKM FamiCord 13. Cells4life 14. Beikebiotech 15. StemCyte 16. Cellsafe Biotech Group 17. PacifiCord 18. Americord 19. Krio 20. Familycord 21. CryoStemcell

Browse Full Report with Facts and Figures Report at:https://www.maximizemarketresearch.com/market-report/stem-cell-banking-market/13540/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Continued here:
Stem Cell Banking Market Industry Analysis & Forecast (2019-2026) by Type, Service, Application and Geography. - Good Night, Good Hockey

Salles Speaks to the Potential Benefit of the Tafasitamab Combo in the R/R DLBCL Setting – Targeted Oncology

On July 31, 2020, the FDA granted accelerated approval to the combination of tafasitamab (Monjuvi) and lenalidomide (Revlimid) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant.1

The approval was granted based on findings from the phase 2 L-MIND trial that assessed the safety and efficacy of the combination of tafasitamab and lenalidomide in patients with relapsed/refractory DLBCL who had received 2 prior lines of therapy, including a CD20-directed therapy, and who are ineligible for high-dose chemotherapy and autologous stem cell transplantation.

In this trial, the trial induced an objective response rate of 60%, with complete responses in 43%. The median duration of response was 21.7 months and 72% had a response lasting at least a year.2

The median progression-free survival (PFS) was 12.1 months with a 50% PFS rate at 1 year and 46% at 18 months. The median overall survival was not reached but 74% were alive at 1 year and 64% at 18 months.

With the observational Re-MIND study, the investigators confirmed the benefit that tafasitamab added to the combination by comparing real-world responses with lenalidomide alone to those in the L-MIND trial. Patients who received lenalidomide alone comparatively had an objective response rate of 34.2% with complete responses in 13.2%. The median PFS was 4.0 months with the monotherapy and the median overall survival was 9.4 months.3

I think its great news for patients with lymphoma and we hope we can offer this form of therapy to them soon and I think this is real progress in the field, Gilles Salles, MD, PhD, told Targeted Oncology about his perspective on the recent approval.

In an interview with Targeted Oncology, Salles, who is professor at the University of Lyon and chair of the Department of Hematology at Centre Hospitalier Lyon-Sud in France, and who will soon be moving to Memorial Sloan Kettering Cancer Center in New York as chief of the Lymphoma Service, explained the unmet needs in DLBCL that may be filled by this new option in the treatment armamentarium and the findings that led to the approval of the combination.

Targeted Oncology: Could you describe the unmet needs in DLBCL that led to the investigation of this combination?

Salles: So DLBCL is the most frequent lymphoma entity. Now more than 30,000 patients are affected [with DLBCL] each [year in the United States].

For patients that are younger and without comorbidities, salvage chemotherapy followed by a stem cell transplant is a standard of care. However, about half of the patients do not respond to salvage chemotherapy. And even after autologous transplant, half of the patients will relapse. And for the other patients that are not transplant eligible, we usually use palliative chemotherapy such as rituximab (Rituxan) and bendamustine or other rituximab and cytotoxicbased regimen. And if those patients fail this salvage regimen, we usually cant go on too long with other regimens, since we are hampered by the cytotoxicity of these different regimens. So there is a real need to improve the outcome of patients that have failed the first line of therapy in DLBCL.

Obviously in the field we have seen CAR T-cell therapy emerging in the recent years. And this has been a major progress, but its a progress that is also hampered by the difficulty of accessing CAR therapy, you need to have this treatment in specialized centers, a significant amount of grade 3/4 adverse effects that are specific to CAR T-cell therapycytokine release syndromes, neurological events, and cytopenias may occur. And it's also not necessarily a treatment for which all patients can be eligible because for patients with a rapidly growing disease there is a waiting time to get the CAR T reinfused and some patients cannot [wait through the manufacturing process]. So, there are clearly some unmet needs.

We have seen polatuzumab vedotin (Polivy), which can be combined with bendamustine and rituximab, and was approved recently and selinexor (Xpovio) also recently [was approved], but they don't necessarily fulfill the whole unmet need in the field.

Could you give some background on the mechanism of action for tafasitamab and why this combination was explored in this setting?

So, tafasitamab is a CD19 fFc-enhanced monoclonal antibody that will mobilize the effector cells such as NK cells and macrophages and enhance their cytotoxic activity against tumor cells. As a single agent, it has demonstrated safety and modest efficacy, but there was a rationale based on this mechanism of action to combine it with lenalidomide, which has been shown previously to enhance the NK activity and in vitro studies have demonstrated the potential of this combination.

The L-MIND study was a study evaluating [this combination] in patients with relapsed/refractory DLBCL that were non-transplant eligible. The combination of lenalidomide administered in 21 out of 28-day cycles, with tafasitamab injected, initially weekly, and then every 2 weeks. This combination period lasted one year then tafasitamab alone was then administered every 2 weeks in patients that benefited from this combination.

What did the L-MIND study show?

The main results of the studies that have been published recently in Lancet Oncology had shown that there was a response rate of around 60%. So, the majority of patients responded to this form of combination, and 43% of the patients achieved a complete response, which was usually rapidly achieved at the time of the third cycle of therapy. What was really meaningful is the duration of response, which has been reported recently is in the range of 21 months, which is remarkable for this kind of therapy in this population of patients.

The adverse events after receiving this treatment were essentially hematologic, a few rashes, a few gastrointestinal symptomswhich are usual when you administer lenalidomide to patients. We had about 50% of the patients experiencing grades 3/4 neutropenia, about 20% experiencing thrombocytopenia, and a few other adverse events and they were manageable for the majority of patients. Furthermore, while this event occurs essentially during the first year of the treatment for those responders that continued on tafasitamab alone, there were very few events that were observed in these patients showing that the majority of these events were really linked to the administration of lenalidomide.

The patients in the study had a prolonged overall survival also, demonstrating that there was a benefit for this population. So it's an interesting combination, which is a chemotherapy-free combination that can be used in those patients that are non-transplant eligible, according to the approval label, and are already at their first failure after R-CHOP, and obviously at later lines if needed.

How did the observational Re-MIND study contribute to the findings for the benefit achieved by the combination in this setting?

The Re-MIND study was a comparison of observational data regarding the use of lenalidomide as a single agent in the same populations as the L-MIND study. A comparison was made then between the patients recruited in the trial and the patients that received lenalidomide in real life. And what the Re-MIND study has shown was that clearly, there was an increase over response rates, CR rates, and PFS for those patients that received the combination, clearly showing that tafasitamab was adding a potential therapeutic benefit compared to those patients that received lenalidomide alone, further confirming the synergy of the combination.

What are some of the safety concerns that you've seen with this combination? And how can these adverse events be managed?

The adverse events that we see are essentially hematologic with about 50% of patients experiencing a grade 3 or 4 neutropenia, and about 20%, thrombocytopenia. Most of them are reversible and we have recently updated the trial showing that the frequency of neutropenia during the first year of treatment is around 1.1 per patient year, and the frequency of thrombocytopenia is about 0.2 per patient year.4 It's events that we know how to manage and in most cases, they don't require hospitalization, they don't require transfusion. This is clearly an ambulatory treatment. The other adverse effects are those relating to lenalidomidea few rashes, gastrointestinal symptoms, but nothing that we can't manage easily in these patients. Obviously, I will say that this regimen is well tolerated. There are very few febrile neutropenias, a few infections. And I think it's a regimen that is particularly suitable for those patients that are non-transplant eligible.

Given the safety profile of this combination of tafasitamab plus lenalidomide, this regimen is particularly suitable for a large proportion of patients with DLBCL. We do know that the median age of occurrence of DLBCL is in the late 60s and there are many, many patients that are over 70 and that are not usually transplant eligible. Clearly this is a great opportunity for patients to receive this non cytotoxic regimen.

What is your perspective of how this combination will fit into the overall treatment paradigm for relapsed/refractory DLBCL, and what do you think is the overall impact of this approval?

I think it will be a new treatment option for patients with non-transplant eligible DLBCL and those patients could be offered to receive this regimen either at first relapse after R-CHOP or if they fail the first salvage conventional chemo. This treatment then can be proposed to many patients. And there are also those patients that were transplant eligible but will fail to respond to salvage therapy or those who relapse after transplant and then became eligible to receive this combination.

So, I am confident there is a large proportion of patients that can benefit from this option. And I see it as one of the major options in the relapsed/refractory setting for those patients who are not designated to go down the path of transplant or who have failed this path. And I think this is important.

What is unknown at this time is how this regimen will be combined or how it will sequence with CAR T programs. We have no experience, or very limited experience, of patients receiving this regimen before CAR T. But there is anecdotal evidence that this can be achieved. So, whether it can be used or bridging or not, I think we have insufficient data and because it targets the same antigen at CAR T, which is CD19 there clearly should be some precaution in order to use this regimen before CAR T. But, we need to have more data in this field. For those patients that had failed CAR T-cell therapy, substantial proportions, about 30% of them, may have lost CD19 expression and then may not be eligible anymore for this regimen. There is, however, a substantial proportion of patients that retains CD19 and in whom tafasitamab/lenalidomide can be used as a treatment option.

So, I believe it will be one of the regimens that will be rapidly used by many physicians and proposed to patients as one of the options that we have in this setting.

References:

1. FDA Approves Monjuvi (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL). News release. MorphoSys AG and Incyte. July 31, 2020. Accessed August 7, 2020. https://bit.ly/3fgyqZZ

2. Salles G, Duell J, Barca EG, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978-988. doi:10.1016/S1470-2045(20)30225-4

3. Zinzani PL, Rodgers T, Marino D, et al. RE-MIND study: Comparison of tafasitamab + lenalidomide (L-MIND) vs lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma. Presented at: European Hematology Association Virtual Congress; June 11-21, 2020. Abstract S238.

4. Salles G, Duell J, Gonzlez-Barca E, et al. Long-term outcomes from the phase II L-MIND study of Tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Presented at: European Hematology Association Virtual Congress; June 11-21, 2020. Abstract EP1201.

Originally posted here:
Salles Speaks to the Potential Benefit of the Tafasitamab Combo in the R/R DLBCL Setting - Targeted Oncology